Eltek Ltd.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Exhibit 99.1

Press Release
Eltek Ltd. Reports Second-Quarter 2026 Results
Petach Tikva, Israel (August 18, 2026) Eltek Ltd.
(NASDAQ: ELTK), a leading global manufacturer of high-quality printed circuit boards, today announced its financial results for
the quarter ended June 30, 2026.
Second Quarter 2026 Highlights
| § | Revenues were $11.5 million |
| § | Operating loss was $2.5 million |
| § | Net loss was $2.7 million or $0.41 per fully diluted
share |
| § | Net cash provided by operating activities amounted
to $0.7 million. |
Eli Yaffe, Chief Executive Officer, stated:
“Our second-quarter 2026 results reflected
a loss as we remain in an important transition period focused on stabilizing our manufacturing operations and building the human and operational
infrastructure required to support our next phase of growth. The stabilization of our production system and the integration of our new
production lines are progressing, although the process is not yet complete.
We are well advanced in the implementation of
our new ERP system, which we believe will provide a stronger foundation for managing and scaling our operations. We are also completing
the installation of our newly arrived PCB plating line, while conducting acceptance testing in parallel, and expect to begin the qualification
process during the third quarter.
Although the transition is not yet complete,
we are making steady progress across the key areas of our business. We remain focused on completing the stabilization of our manufacturing
operations, strengthening our organization and infrastructure and improving operational efficiency. We believe these steps are establishing
a stronger foundation for improved operational and financial performance in the periods ahead.”
Second Quarter 2026 GAAP Financial Results
Revenues for the second quarter of 2026
were $11.5 million compared to $12.5 million in the second quarter of 2025.
Gross loss for the second quarter of 2026
was $1.0 million compared to gross profit of $3.0 million (24% of revenues) in the second quarter of 2025.
Operating loss for the second quarter of
2026 was $2.5 million compared to operating profit of $1.5 million in the second quarter of 2025.
Financial expenses for the second quarter
of 2026 were $0.7 million compared to $1.0 million in the second quarter of 2025. Financial expenses primarily resulted from the erosion
of the U.S. dollar against the NIS.
Net loss for the second quarter of 2026
was $2.7 million or $0.41 per fully diluted share compared to net income of $0.4 million or $0.05 per fully diluted share in the second
quarter of 2025.
Second Quarter 2026 Non-GAAP Financial Results
EBITDA loss for the second quarter of 2026
was $1.9 million compared to EBITDA of $2.0 million (15.6% of revenues) in the second quarter of 2025.
Six Months Ended June 30, 2026 GAAP Financial
Results
Revenues for the first six months of 2026
were $22.0 million compared to $25.3 million in the first six months of 2025.
Gross loss for the first six months of
2026 was $2.8 million compared to gross profit of $5.2 million (21% of revenues) in the first six months of 2025.
Operating loss for the first six months
of 2026 was $5.8 million compared to operating profit of $2.2 million in the first six months of 2025.
Financial expenses for the first six months
of 2026 were $0.8 million compared to $0.5 million in the first six months of 2025. Financial expenses primarily resulted from the erosion
of the U.S. dollar against the NIS.
Net loss for the first six months of 2026
was $5.6 million or $0.83 per fully diluted share compared to net profit of $1.4 million or $0.20 per fully diluted share in the first
six months of 2025.
Six Months Ended June 30, 2026 Non-GAAP Financial
Results
EBITDA loss for the first six months of
2026 was a $4.6 million compared to EBITDA of $3.1 million (12% of revenues) in the first six months of 2025.
About our Non-GAAP Financial Information
The Company reports financial results in accordance
with U.S. GAAP and herein provides EBITDA, a non-GAAP measure. This non-GAAP measure is not in accordance with, nor is it a substitute
for, GAAP measures. This non-GAAP measure is intended to supplement the Company’s presentation of its financial results that are
prepared in accordance with GAAP. The Company uses the non-GAAP measure presented to evaluate and manage the Company’s operations
internally. The Company is also providing this information to assist investors in performing additional financial analysis. Reconciliation
between the Company's results on a GAAP and non-GAAP basis is provided in a table below.
Conference Call
Today, Tuesday, August 18, 2026, at 8:30am Eastern
Time (15:30pm Israel Time, 5:30am Pacific Time), Eltek will conduct a conference call to discuss the results. The call will feature remarks
by Eli Yaffe, Chief Executive Officer and Ron Freund, Chief Financial Officer.
To participate, please call the following teleconference
numbers. Please allow for additional time to connect prior to the call:
| United States: |
1-866-860-9642 |
| |
|
| Israel: |
03-918-0691 |
| |
|
| International: |
+972-3-918-0691 |
To Access a Replay of the Call
A replay of the call will be available for 30
days on the Investor Info section on Eltek’s corporate website at http://www.nisteceltek.com approximately 24 hours after
the conference call is completed.
About Eltek
Eltek – ”Innovation Across the Board”,
is a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards (PCBs) and is an Israeli
leading company in this industry. PCBs are the core circuitry of most electronic devices. Eltek specializes in the manufacture and supply
of complex and high-quality PCBs, HDI, multilayered and flex-rigid boards for the high-end market. Eltek is ITAR compliant and has AS-9100
and NADCAP Electronics certifications. Its customers include leading companies in the defense, aerospace and medical industries in Israel,
the United States, Europe and Asia.
Eltek was founded in 1970. The Company’s
headquarters, R&D, production and marketing center are located in Israel. Eltek also operates through its subsidiary in North America
and by agents and distributors in Europe, India, South Africa and South America.
For more information, visit Eltek's web site at
www.nisteceltek.com
Forward Looking Statement
Some of the statements included in this press
release may be forward-looking statements that involve a number of risks and uncertainties including, but not limited to expected results
in future quarters, the impact of currency movements between the US Dollar exchange rate against the Israeli Shekel, the impact of the
Coronavirus on the economy and our operations, risks in product and technology development and rapid technological change, product demand,
the impact of competitive products and pricing, market acceptance, the sales cycle, changing economic conditions and other risk factors
detailed in the Company’s Annual Report on Form 20-F and other filings with the United States Securities and Exchange Commission.
Any forward-looking statements set forth in this press release speak only as of the date of this press release. The information found
on our website is not incorporated by reference into this press release and is included for reference purposes only.
Investor Contact
Ron Freund
Chief Financial Officer
Investor-Contact@nisteceltek.com
+972-3-939-5023
(Tables follow)
| Eltek Ltd. |
| Consolidated Statements of Income |
| U.S dollars in thousands (except per share data) |
| | |
Three months ended | | |
Six months ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| |
| Revenues | |
| 11,534 | | |
| 12,529 | | |
| 21,970 | | |
| 25,285 | |
| Costs of revenues | |
| (12,498 | ) | |
| (9,510 | ) | |
| (24,786 | ) | |
| (20,054 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Gross profit (loss) | |
| (964 | ) | |
| 3,019 | | |
| (2,816 | ) | |
| 5,231 | |
| | |
| | | |
| | | |
| | | |
| | |
| Research and development expenses, net | |
| - | | |
| - | | |
| 0 | | |
| (50 | ) |
| Selling, general and administrative expenses | |
| (1,582 | ) | |
| (1,563 | ) | |
| (2,997 | ) | |
| (3,000 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Operating income (loss) | |
| (2,546 | ) | |
| 1,456 | | |
| (5,813 | ) | |
| 2,181 | |
| | |
| | | |
| | | |
| | | |
| | |
| Financial expense, net | |
| (698 | ) | |
| (1,012 | ) | |
| (792 | ) | |
| (508 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Income (loss) before income tax | |
| (3,244 | ) | |
| 444 | | |
| (6,605 | ) | |
| 1,673 | |
| | |
| | | |
| | | |
| | | |
| | |
| Income tax expenses (tax benefit) | |
| (500 | ) | |
| 79 | | |
| (1,008 | ) | |
| 306 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) | |
| (2,744 | ) | |
| 365 | | |
| (5,597 | ) | |
| 1,367 | |
| | |
| | | |
| | | |
| | | |
| | |
| Earnings per share: | |
| | | |
| | | |
| | | |
| | |
| Basic net income (loss) per ordinary share | |
| (0.41 | ) | |
| 0.05 | | |
| (0.83 | ) | |
| 0.20 | |
| | |
| | | |
| | | |
| | | |
| | |
| Diluted net income (loss) per ordinary share | |
| (0.41 | ) | |
| 0.05 | | |
| (0.83 | ) | |
| 0.20 | |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average number of ordinary shares used to compute | |
| | | |
| | | |
| | | |
| | |
| basic net income (loss) per ordinary share (in thousands) | |
| 6,720 | | |
| 6,715 | | |
| 6,720 | | |
| 6,715 | |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average number of ordinary shares used to compute | |
| | | |
| | | |
| | | |
| | |
| diluted net income (loss) per ordinary share (in thousands) | |
| 6,785 | | |
| 6,784 | | |
| 6,785 | | |
| 6,785 | |
| Eltek Ltd. |
| Consolidated Balance Sheets |
| U.S dollars in thousands |
| | |
June 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| | |
| |
| Assets | |
| | | |
| | |
| | |
| | | |
| | |
| Current assets: | |
| | | |
| | |
| Cash and cash equivalents | |
| 9,390 | | |
| 2,481 | |
| Short-term bank deposits | |
| 2,117 | | |
| 9,643 | |
| Trade receivables (net of allowance for credit losses) | |
| 11,656 | | |
| 14,789 | |
| Inventories | |
| 10,295 | | |
| 11,154 | |
| Other accounts receivable and prepaid expenses | |
| 970 | | |
| 607 | |
| | |
| | | |
| | |
| Total current assets | |
| 34,428 | | |
| 38,674 | |
| | |
| | | |
| | |
| Long term assets: | |
| | | |
| | |
| Severance pay fund | |
| 76 | | |
| 65 | |
| Deferred tax assets, net | |
| 1,504 | | |
| 387 | |
| Operating lease right of use assets | |
| 12,466 | | |
| 6,272 | |
| Total long term assets | |
| 14,046 | | |
| 6,724 | |
| | |
| | | |
| | |
| Property and equipment, net | |
| 24,664 | | |
| 20,862 | |
| | |
| | | |
| | |
| Total Assets | |
| 73,138 | | |
| 66,260 | |
| | |
| | | |
| | |
| Liabilities and Shareholder's equity | |
| | | |
| | |
| | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Trade payables | |
| 8,544 | | |
| 6,047 | |
| Other accounts payable and accrued expenses | |
| 6,735 | | |
| 6,565 | |
| Short-term operating lease liabilities | |
| 718 | | |
| 1,100 | |
| | |
| | | |
| | |
| Total current liabilities | |
| 15,997 | | |
| 13,712 | |
| | |
| | | |
| | |
| Long-term liabilities: | |
| | | |
| | |
| Accrued severance pay | |
| 578 | | |
| 515 | |
| Long-term operating lease liabilities | |
| 12,199 | | |
| 5,296 | |
| | |
| | | |
| | |
| Total long-term liabilities | |
| 12,777 | | |
| 5,811 | |
| | |
| | | |
| | |
| Shareholders' equity: | |
| | | |
| | |
| Ordinary shares of NIS 3.0 par value – Authorized: 10,000,000 shares at June 30, 2026 and December 31, 2025; Issued and outstanding: 6,720,827 shares at June 30, 2026 and 6,719,827 shares at December 31, 2025 | |
| 6,012 | | |
| 6,012 | |
| Foreign currency translation adjustments | |
| 9,088 | | |
| 6,111 | |
| Additional paid-in capital | |
| 35,928 | | |
| 35,681 | |
| Accumulated deficit | |
| (6,664 | ) | |
| (1,067 | ) |
| Total shareholders' equity | |
| 44,364 | | |
| 46,737 | |
| Total liabilities and shareholders' equity | |
| 73,138 | | |
| 66,260 | |
| Eltek Ltd. |
| Unaudited Non-GAAP EBITDA Reconciliations |
| U.S dollars in thousands |
| | |
Three months ended | | |
Six months ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| |
| GAAP net income (loss) | |
| (2,744 | ) | |
| 365 | | |
| (5,597 | ) | |
| 1,367 | |
| Add back items: | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Financial expenses (income), net | |
| 698 | | |
| 1,012 | | |
| 792 | | |
| 508 | |
| Income tax expenses (benefit) | |
| (500 | ) | |
| 79 | | |
| (1,008 | ) | |
| 306 | |
| Depreciation | |
| 613 | | |
| 500 | | |
| 1,203 | | |
| 966 | |
| Non-GAAP EBITDA | |
| (1,933 | ) | |
| 1,956 | | |
| (4,610 | ) | |
| 3,147 | |
| Eltek Ltd. |
| Consolidated Statement of Cash flow |
| U.S dollars in thousands |
| | |
Three months ended | | |
Six months ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Cash flows from operating activities: | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Net Income (loss) | |
| (2,744 | ) | |
| 365 | | |
| (5,597 | ) | |
| 1,367 | |
| Adjustments to reconcile net income to net cash flows | |
| | | |
| | | |
| | | |
| | |
| provided by operating activities: | |
| | | |
| | | |
| | | |
| | |
| Depreciation | |
| 613 | | |
| 500 | | |
| 1,203 | | |
| 967 | |
| Unrealized financing expenses (income), net | |
| (86 | ) | |
| 595 | | |
| (155 | ) | |
| 466 | |
| Share-based compensation | |
| 127 | | |
| 132 | | |
| 242 | | |
| 270 | |
| Decrease in deferred tax assets | |
| (534 | ) | |
| 120 | | |
| (1,064 | ) | |
| 202 | |
| | |
| 120 | | |
| 1,347 | | |
| 226 | | |
| 1,905 | |
| | |
| | | |
| | | |
| | | |
| | |
| Decrease (increase) in operating lease right-of-use assets | |
| 162 | | |
| (1 | ) | |
| 311 | | |
| - | |
| Decrease (increase) in trade receivables | |
| 470 | | |
| (1,378 | ) | |
| 4,088 | | |
| (1,733 | ) |
| Decrease (increase) in other receivables and prepaid expenses | |
| (224 | ) | |
| 314 | | |
| (312 | ) | |
| 247 | |
| Decrease (increase) in inventories | |
| (281 | ) | |
| (2,282 | ) | |
| 1,614 | | |
| (2,612 | ) |
| Increase (decrease) in trade payables | |
| 2,736 | | |
| (1,138 | ) | |
| 229 | | |
| (2,000 | ) |
| Increase (decrease) in other liabilities and accrued expenses | |
| 424 | | |
| (201 | ) | |
| (290 | ) | |
| (28 | ) |
| Increase (decrease) in employee severance benefits, net | |
| 11 | | |
| 39 | | |
| 20 | | |
| 46 | |
| | |
| 3,298 | | |
| (4,647 | ) | |
| 5,660 | | |
| (6,080 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net cash provided by (used in) operating activities | |
| 674 | | |
| (2,935 | ) | |
| 289 | | |
| (2,808 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Cash flows from investing activities: | |
| | | |
| | | |
| | | |
| | |
| Purchase of fixed assets | |
| (934 | ) | |
| (1,743 | ) | |
| (1,673 | ) | |
| (2,880 | ) |
| Withdrawal of (investment in) short-term bank deposits, net | |
| (2,092 | ) | |
| - | | |
| 7,620 | | |
| 534 | |
| Net cash provided by (used in) investing activities | |
| (3,026 | ) | |
| (1,743 | ) | |
| 5,947 | | |
| (2,346 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Cash flows from financing activities: | |
| | | |
| | | |
| | | |
| | |
| Exercise of options | |
| 5 | | |
| 8 | | |
| 5 | | |
| 8 | |
| Dividend distribution | |
| - | | |
| (1,276 | ) | |
| - | | |
| (1,276 | ) |
| Issuance of shares, net | |
| - | | |
| - | | |
| - | | |
| - | |
| Net cash provided by (used in) financing activities | |
| 5 | | |
| (1,268 | ) | |
| 5 | | |
| (1,268 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Effect of translation adjustments | |
| 683 | | |
| 1,250 | | |
| 668 | | |
| 617 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net increase (decrease) in cash and cash equivalents | |
| (1,664 | ) | |
| (4,696 | ) | |
| 6,909 | | |
| (5,805 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Cash and cash equivalents at the beginning of the period | |
| 11,054 | | |
| 6,466 | | |
| 2,481 | | |
| 7,575 | |
| | |
| | | |
| | | |
| | | |
| | |
| Cash and cash equivalents at the end of the period | |
| 9,390 | | |
| 1,770 | | |
| 9,390 | | |
| 1,770 | |